In vitro effects of bufotenine against RNA and DNA viruses

Barboza, Camila Mosca; Pimenta, Daniel Carvalho; Vigerelli, Hugo; Silva, Andréa de Cássia Rodrigues da; Garcia, Jaíne Gonçalves; Zamudio, Raphaela Mello; Castilho, Juliana Galera; Montanha, Jarbas Alves; Roehe, Paulo Michel; Batista, Helena Beatriz de Carvalho Ruthner

doi:10.1007/s42770-021-00612-1

Cited by 6 publications

(5 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to high toxicity of the conventional antiviral drugs, numerous natural substances are being recently tested to conceive new therapeutics against viral infections. On this regard, natural products, such as bufotenine, an alkaloid obtained by skin secretions of amphibians and plant extracts, did not show potential antiviral activity against CCoV infection [ 50 ].…”

Section: Discussionmentioning

confidence: 99%

Fungal metabolite 6-pentyl-α-pyrone reduces canine coronavirus infection

Cerracchio,

Del Sorbo,

Serra

et al. 2024

Heliyon

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Fungal metabolite 6-pentyl-α-pyrone reduces canine coronavirus infection

Cerracchio,

Del Sorbo,

Serra

et al. 2024

Heliyon

View full text Add to dashboard Cite

“…When determining the effectiveness of the proposed interventions, five (3.65%) were shown not to be effective [ 84 , 107 , 126 , 131 , 139 ], three (2.19%) were somewhat effective [ 21 , 46 , 53 ], and 128 (93.43%) were effective as potential managements for resistant strains of HSV [ 1 - 3 , 6 - 20 , 22 - 45 , 47 - 52 , 54 - 56 , 58 - 83 , 85 - 106 , 108 - 125 , 127 - 130 , 132 - 138 ].…”

Section: Reviewmentioning

confidence: 99%

“…When determining the effectiveness of the proposed interventions, five (3.65%) were shown not to be effective [84,107,126,131,139], three (2.19%) were somewhat effective [21,46,53], and 128 (93.43%) were effective as potential managements for resistant strains of HSV [1][2][3][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][47][48][49][50][51][52][54][55][56][108][109][110][111][112][113][114][115][116][117][118][119][120][121][122]…”

Section: Data Extractionmentioning

confidence: 99%

A Systematic Review of Second-Line Treatments in Antiviral Resistant Strains of HSV-1, HSV-2, and VZV

Lince¹,

DeMario²,

Yang³

et al. 2023

Cureus

View full text Add to dashboard Cite

Drug-resistant variants of herpes simplex viruses (HSV) have been reported that are not effectively treated with first-line antiviral agents. The objective of this study was to evaluate available literature on the possible efficacy of second-line treatments in HSV and the use of second-line treatments in HSV strains that are resistant to first-line treatments. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a final search was conducted in six databases on November 5, 2021 for all relevant literature using terms related to antiviral resistance, herpes, and HSV. Eligible manuscripts were required to report the presence of an existing or proposed second-line treatment for HSV-1, HSV-2, or varicella zoster virus (VZV); have full-text English-language access; and potentially reduce the rate of antiviral resistance. Following screening, 137 articles were included in qualitative synthesis. Of the included studies, articles that examined the relationship between viral resistance to first-line treatments and potential second-line treatments in HSV were included. The Cochrane risk-of-bias tool for randomized trials was used to assess risk of bias. Due to the heterogeneity of study designs, a meta-analysis of the studies was not performed. The dates in which accepted studies were published spanned from 2015-2021. In terms of sample characteristics, the majority (72.26%) of studies used Vero cells. When looking at the viruses on which the interventions were tested, the majority (84.67%) used HSV-1, with (34.31%) of these studies reporting testing on resistant HSV strains. Regarding the effectiveness of the proposed interventions, 91.97% were effective as potential managements for resistant strains of HSV. Of the papers reviewed, nectin in 2.19% of the reviews had efficacy as a second-line treatments in HSV, amenamevir in 2.19%, methanol extract in 2.19%, monoclonal antibodies in 1.46%, arbidol in 1.46%, siRNA swarms in 1.46%, Cucumis melo sulfated pectin in 1.46%, and components from Olea europeae in 1.46%. In addition to this griffithsin in 1.46% was effective, Morus alba L. in 1.46%, using nucleosides in 1.46%, botryosphaeran in 1.46%, monoterpenes in 1.46%, almond skin extracts in 1.46%, bortezomib in 1.46%, flavonoid compounds in 1.46%, andessential oils were effective in 1.46%, but not effective in 0.73%. The available literature reviewed consistently supports the existence and potentiality of second-line treatments for HSV strains that are resistant to first-line treatments. Immunocompromised patients have been noted to be the population most often affected by drug-resistant variants of HSV. Subsequently, we found that HSV infections in this patient population are challenging to manage clinically effectively. The goal of this systematic review is to provide additional information to patients on the potentiality of second-line treatment in HSV strains resistant to first-line treatments, especially those who are immunocompromised. All patients,...

show abstract

“…Norpsilocin, baeocystin, norbaeocystin, aeruginascin, and bufotenin ( 67 – 71 , Figure 5 ) are other examples of indoles with psychoactive properties produced by mushrooms, although they have not been studied much other than psilocin or psilocybin [ 21 , 108 ]. The syntheses and biological evaluation of some of these were carried out by Sherwood et al (2020) [ 108 ], and the antiviral activity of bufotenine ( 71 ) was reported [ 109 ]. Norpsilocin ( 67 ) was isolated for the first time in 2017 (from Psilocybe cubensis ) and its psychoactive properties, with an agonist activity of the human 5-HT 2A receptor close to that of psilocin ( 64 ), were also described [ 110 ].…”

Section: New Alkaloids Found In Mushroom Since 2002mentioning

confidence: 99%

Structures and Biological Activities of Alkaloids Produced by Mushrooms, a Fungal Subgroup

Zorrilla

Evidente

2022

Biomolecules

View full text Add to dashboard Cite

Alkaloids are a wide family of basic N-containing natural products, whose research has revealed bioactive compounds of pharmacological interest. Studies on these compounds have focused more attention on those produced by plants, although other types of organisms have also been proven to synthesize bioactive alkaloids, such as animals, marine organisms, bacteria, and fungi. This review covers the findings of the last 20 years (2002–2022) related to the isolation, structures, and biological activities of the alkaloids produced by mushrooms, a fungal subgroup, and their potential to develop drugs and agrochemicals. In some cases, the synthesis of the reviewed compounds and structure−activity relationship studies have been described.

show abstract

In vitro effects of bufotenine against RNA and DNA viruses

Cited by 6 publications

References 31 publications

Fungal metabolite 6-pentyl-α-pyrone reduces canine coronavirus infection

Fungal metabolite 6-pentyl-α-pyrone reduces canine coronavirus infection

A Systematic Review of Second-Line Treatments in Antiviral Resistant Strains of HSV-1, HSV-2, and VZV

Structures and Biological Activities of Alkaloids Produced by Mushrooms, a Fungal Subgroup

Contact Info

Product

Resources

About